Related Experiment Videos
[The effect of amiridin on the MPTP-induced Parkinson-like syndrome in monkeys]
Biulleten' Eksperimental'Noi Biologii I Meditsiny
|November 1, 1992
Abstract:
Development of behavioral disturbances was investigated during N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration (0,2 mg/kg, i/m, at 48 h. intervals, total dose 11.2-13.2 mg/kg) in experiments on two monkeys Macaca rhesus. MPTP induced the complex of symptoms, which are typical for idiopathic Parkinson's disease. Administration of amiridine (0,25-0,4 mg/kg) to MPTP-treated monkeys caused gradual decline of Parkinson syndrome. Mechanisms of action of amiridine are discussed.
Insights
N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced Parkinson
Area of Science:
- Neuroscience
- Pharmacology
- Primate Models
Context:
- Investigating behavioral disturbances in Macaca rhesus monkeys.
- Utilizing N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) as a neurotoxin.
- Studying models of idiopathic Parkinson's disease.
Purpose:
- To examine the development of behavioral disturbances induced by MPTP.
- To evaluate the therapeutic potential of amiridine in an MPTP-induced Parkinson's model.
- To explore the mechanisms underlying amiridine's action.
Summary:
- MPTP administration in rhesus monkeys reliably induced a Parkinsonian syndrome.
- Treatment with amiridine led to a progressive reduction of these Parkinsonian symptoms.
- The study discusses the potential mechanisms of amiridine's therapeutic effects.
Impact:
- Provides insights into MPTP-induced neurotoxicity and Parkinsonism.
- Suggests amiridine as a potential therapeutic agent for Parkinson's disease.
- Contributes to understanding drug mechanisms in neurodegenerative disease models.